Published in Pediatr Endocrinol Rev on March 01, 2011
Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metab (2013) 1.16
β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica (2015) 1.06
Serum hepcidin and chronic obstructive pulmonary disease. Ann Thorac Med (2012) 0.96
Epidural anesthesia for laparoscopic cholecystectomy in a patient with sickle cell anemia, beta thalassemia, and Crohn's disease -A case report-. Korean J Anesthesiol (2012) 0.80
Protection against oxidative stress in beta thalassemia/hemoglobin E erythrocytes by inhibitors of glutathione efflux transporters. PLoS One (2013) 0.78
Assessment of the red cell proteome of young patients with unexplained hemolytic anemia by two-dimensional differential in-gel electrophoresis (DIGE). PLoS One (2012) 0.76
From the Cradle to the Grave: The Role of Macrophages in Erythropoiesis and Erythrophagocytosis. Front Immunol (2017) 0.75
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A (2008) 5.27
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica (2008) 2.92
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood (2005) 2.75
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica (2005) 2.64
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica (2006) 2.54
Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica (2005) 2.53
Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica (2007) 2.52
Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet (2011) 2.51
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
Beta-thalassemia. Genet Med (2010) 2.24
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Purging iron from the heart. Br J Haematol (2004) 2.07
Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet (2009) 1.87
Thalassemia. Hematology Am Soc Hematol Educ Program (2004) 1.83
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood (2002) 1.77
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson (2008) 1.76
KLF1 gene mutations cause borderline HbA(2). Blood (2011) 1.71
In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. Blood Cells Mol Dis (2002) 1.70
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am (2002) 1.50
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood (2003) 1.46
Pregnancy and beta-thalassemia: an Italian multicenter experience. Haematologica (2009) 1.42
Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica (2008) 1.24
Compound heterozygosity for KLF1 mutations associated with remarkable increase of fetal hemoglobin and red cell protoporphyrin. Haematologica (2011) 1.23
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol (2002) 1.21
International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging (2010) 1.14
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation (2013) 1.11
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica (2011) 1.10
Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study. Circulation (2013) 1.06
Effect of consanguinity on screening for thalassemia. N Engl J Med (2002) 1.05
Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy. Hum Gene Ther (2007) 1.03
Gene test review. Alpha-thalassemia. Genet Med (2011) 1.02
Association of α globin gene quadruplication and heterozygous β thalassemia in patients with thalassemia intermedia. Haematologica (2009) 1.00
Beta-thalassemia: from genotype to phenotype. Haematologica (2011) 1.00
Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. Mol Pharmacol (2007) 0.97
Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. Clin Biochem (2007) 0.96
Reliable detection of beta-thalassemia and G6PD mutations by a DNA microarray. Clin Chem (2002) 0.95
Analytical evaluation of the Tosoh HLC-723 G7 automated HPLC analyzer for hemoglobin A2 and F determination. Clin Biochem (2005) 0.95
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol (2013) 0.95
Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia. Ann N Y Acad Sci (2010) 0.89
No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia. Haematologica (2008) 0.88
Cholelithiasis in thalassemia major. Eur J Haematol (2008) 0.87
Two new beta-thalassemia deletions compromising prenatal diagnosis in an Italian and a Turkish couple seeking prevention. Haematologica (2009) 0.87
Genetic modifiers of β-thalassemia and clinical severity as assessed by age at first transfusion. Haematologica (2012) 0.86
Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report. Eur J Heart Fail (2006) 0.86
Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells Mol Dis (2010) 0.86
Natural history of hepatitis C in thalassemia major: a long-term prospective study. Eur J Haematol (2013) 0.85
An electronic infrastructure for research and treatment of the thalassemias and other hemoglobinopathies: the Euro-mediterranean ITHANET project. Hemoglobin (2009) 0.85
Responsiveness to oral iron and ascorbic acid in a patient with IRIDA. Blood Cells Mol Dis (2011) 0.85
H63D mutation in the HFE gene increases iron overload in beta-thalassemia carriers. Haematologica (2002) 0.84
Thalassemia minor, the Gilbert mutation, and the risk of gallstones. Haematologica (2003) 0.84
Renal aspects of thalassaemia a changing paradigm. Eur J Haematol (2012) 0.84
New analytical tools and epidemiological data for the identification of HbA2 borderline subjects in the screening for beta-thalassemia. Bioelectrochemistry (2008) 0.84
Use of erythropoiesis stimulating agents for the treatment of anaemia and related fatigue in a pregnant woman with HbH disease. Br J Haematol (2009) 0.83
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. J Cardiovasc Magn Reson (2011) 0.82
Recent advances in β-thalassemias. Pediatr Rep (2011) 0.82
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major. Br J Haematol (2013) 0.82
Homozygous deletion of the major alpha-globin regulatory element (MCS-R2) responsible for a severe case of hemoglobin H disease. Blood (2010) 0.82
Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major. J Cardiovasc Magn Reson (2012) 0.82
Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica (2012) 0.81
Frequency of hemochromatosis C282Y and H63D mutations in Sardinia. Genet Test (2002) 0.80
In vivo activation of the human δ-globin gene: the therapeutic potential in β-thalassemic mice. Haematologica (2013) 0.80
α-globin gene quadruplication and heterozygous β-thalassemia: a not so rare cause of thalassemia intermedia. Acta Haematol (2013) 0.79
Delayed fetal hemoglobin switching in subjects with KLF1 gene mutation. Blood Cells Mol Dis (2011) 0.79
Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project. Br J Haematol (2013) 0.78
A decisional algorithm to start iron chelation in patients with beta thalassemia. Haematologica (2014) 0.78
EMQN Best Practice Guidelines for molecular and haematology methods for carrier identification and prenatal diagnosis of the haemoglobinopathies. Eur J Hum Genet (2015) 0.78
Seasonal variation of pretransfusion hemoglobin levels in patients with thalassemia major. Blood (2005) 0.77
Changing patterns of splenectomy in transfusion-dependent thalassemia patients. Am J Hematol (2011) 0.77
Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study. Eur J Echocardiogr (2011) 0.77
Iron-deficiency anemia secondary to mutations in genes controlling hepcidin. Expert Rev Hematol (2010) 0.76
Identification and functional characterization of a new hemoglobin variant in Sardinia: Hb Muravera [beta47 GAT->GTT, (CD6) Asp->Val]. Haematologica (2002) 0.76
Complexity of the alpha-globin genotypes identified with thalassemia screening in Sardinia. Blood Cells Mol Dis (2013) 0.76
ThalassoChip, an array mutation and single nucleotide polymorphism detection tool for the diagnosis of β-thalassaemia. Clin Chem Lab Med (2010) 0.76
Experiences in the measurement of RBC-bound IgG as markers of cell age. Bioelectrochemistry (2004) 0.76
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. Am J Hematol (2013) 0.76
Two atypical forms of HbH disease in Sardinia. Haematologica (2011) 0.75
Structural and Functional Characterization of a New Double Variant Haemoglobin (HbG-Philadelphia/Duarte α(2)β(2)). ISRN Hematol (2010) 0.75
First detection of Hb Taybe [α38(C3) or α39(C4) Thr→0 (α1)] in an Italian child. Hemoglobin (2012) 0.75